Q-omics provides the consensus-scored SORD2P profile across patient tissues and cancer cell-line models. SORD2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SORD2P is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, SORD2P RNA expression shows 17,433 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where SORD2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORD2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORD2P survival associations across molecular data types. SORD2P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORD2P RNA expression–survival associations across cancer types. High SORD2P expression shows unfavorable associations in MESO, ACC, SKCM and UVM, but favorable associations in LIHC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SORD2P RNA expression.
This table summarizes SORD2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SORD2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORD2P shows lower tumor expression in THCA, KIRP, KIRC and KICH and higher tumor expression in COAD and LUSC. The THCA box plot shows higher SORD2P RNA expression in normal versus tumor tissue (log2 FC = −1.868, t-test p < 0.001).
This table shows molecular features associated with SORD2P in patient tissues and cancer cell lines. In patient samples, SORD2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SORD2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
